Next Article in Journal / Special Issue
Glibenclamide for the Treatment of Acute CNS Injury
Previous Article in Journal
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression
Previous Article in Special Issue
A Potent (R)-alpha-bis-lipoyl Derivative Containing 8-Hydroxyquinoline Scaffold: Synthesis and Biological Evaluation of Its Neuroprotective Capabilities in SH-SY5Y Human Neuroblastoma Cells
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2013, 6(10), 1221-1286; doi:10.3390/ph6101221

The Use of Central Nervous System Active Drugs During Pregnancy

Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden
Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden
Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden
Author to whom correspondence should be addressed.
Received: 1 July 2013 / Revised: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013
(This article belongs to the Special Issue CNS-Drugs and Therapy)
View Full-Text   |   Download PDF [328 KB, uploaded 10 October 2013]   |  


CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register. An association between malformations and maternal use of anticonvulsants and notably valproic acid is well known from the literature and also demonstrated in the present study. Some other associations between drug exposure and outcome were found. View Full-Text
Keywords: CNS active drugs; opioids; sedatives; hypnotics; antidepressants; psychostimulants; congenital malformations; neonatal morbidity CNS active drugs; opioids; sedatives; hypnotics; antidepressants; psychostimulants; congenital malformations; neonatal morbidity

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Källén, B.; Borg, N.; Reis, M. The Use of Central Nervous System Active Drugs During Pregnancy. Pharmaceuticals 2013, 6, 1221-1286.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top